Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia

• Therapy-related AML with the t(8;16) is uncommon and associated with a poor prognosis. • Hematopoietic allogeneic stem cell transplantation remains the only curative option. • KAT6A-CREBBP transcript identification is necessary for measurable residual disease. • RT-qPCR monitoring confirms the efficacy of allogeneic stem cell transplantation. • In t(8;16) AML, measurable residual disease peri-transplant may influence prognosis.